POET Technologies ($POET): Can Optical Orders Become Revenue?

01 Three scenarios: funding is in place, commercial execution has to follow

Bull case — qualification becomes repeat production

POET has the financial resources to pursue a manufacturing ramp without depending on immediate profitability. Cash and short-term investments totaled a calculated $796.342 million at June 30, 2026, following substantial equity financing. The favorable scenario is that this capital supports qualified products, timely deliveries and repeat customer orders, while revenue begins to cover a meaningful proportion of operating costs. Financial capacity gives the company time; customer acceptance determines whether that time creates value. Source

The largest disclosed commercial opportunity is the Lumilens relationship. The August 13, 2026 results release described an initial $50 million purchase order within a framework that could exceed $500 million of cumulative purchases over five years. The company’s July 14 explanation makes successful development, qualification and manufacturing expansion conditions for revenue. In the bull case, those conditions are met in a sequence that produces visible deliveries and payments, rather than remaining a large number attached to a development relationship. Source Source

The timetable matters for this scenario. The May 14 announcement expects engineering samples from the Lumilens program in late 2026 and a production ramp aligned to hyperscaler deployments in 2027. Even in the favorable case, the Lumilens order is therefore mainly a 2027 revenue question. Near-term evidence would have to come from the earlier 800G engine order and the production units POET said it would ship for qualification in the remaining quarters of 2026. Source Source

The next positive evidence would therefore be operational: customers accepting production units, repeat orders across products and a growing revenue contribution from shipments. The August 13 announcement also disclosed a separate $2.4 million order received after quarter-end from an existing customer. That shows commercial activity beyond a single headline, although its conversion into recognized revenue still has to appear in later results. A strong outcome would spread revenue across customers and reduce dependence on any one qualification schedule. Source

Base case — commercial progress takes longer than the headline suggests

POET’s second-quarter revenue was $569,925 for the period ended June 30, 2026, up from $503,389 in the first quarter. That is progress from a small base. In a middle scenario, engineering work and initial product shipments grow while manufacturing, staffing and product development continue to absorb cash. Large customer commitments would support the opportunity, but the timing of revenue would remain uneven. Source Source

This scenario can include a healthy balance sheet and continuing losses at the same time. The company announced approximately $50 million of planned equipment investment in the second half of 2026 in its June 30 update. Spending ahead of revenue can be rational when it unlocks qualified demand, but it also raises the amount of commercial success needed to justify the expanded business. The market would have to assess delivery milestones and spending together. Source

Bear case — capacity and dilution arrive before sustainable demand

The adverse scenario is a slower conversion of development programs into accepted products. Qualification delays, changing customer requirements or lower manufacturing yields could push revenue out while the cost base expands. Cash would soften the immediate funding pressure but would not protect the value of the capital invested. A well-funded business can still destroy shareholder value if its production economics disappoint.

Dilution is already part of the starting position. POET reported 173,058,088 common shares outstanding on August 13, 2026, as well as 78,734,968 outstanding warrants. Those warrants include customer awards subject to vesting conditions, so they are not all immediately exercisable, but they remain economically relevant. The bear case becomes stronger if revenue expectations keep moving outward while the eventual ownership denominator grows. Source Source

What Would Falsify This Reading

The analysis rests on POET being funded for a commercial transition whose operating outcome still depends on customer acceptance. The following developments would materially change that reading.

• Evidence that revenue has reached a repeatable production base. Accepted deliveries across customers, repeat orders and collections sufficient to narrow operating consumption would strengthen the case beyond the small revenue base reported for June 2026. The next results need to connect sales with cash rather than only repeat the potential order value. Source Source
• A material delay or change in customer conditions. Revised qualification requirements, a postponed production window or weaker customer commitments would reduce the confidence attached to the disclosed Lumilens opportunity. Its development and manufacturing conditions remain central to the company’s July 14 explanation. Source
• Capital use that changes the financial cushion. A materially larger equipment program, strategic transaction or operating deficit could make the June 30 liquidity balance a less useful guide to subsequent flexibility. Conversely, productive capacity delivered within the announced investment plan would strengthen execution credibility. Source Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 The business: optical connections for AI infrastructure

POET develops optical engines, light sources and optical modules for artificial intelligence systems and data centers. Its Optical Interposer combines electronic and photonic components using semiconductor manufacturing techniques. The commercial aim is to simplify integration and offer customers attractive cost, power and manufacturing characteristics. These are product advantages the company must demonstrate in customer applications and at production scale. Source

For a trader, the important distinction is between technical promise and an economically established supplier. A product can perform in a demonstration and still require customer qualification, manufacturing refinement and commercial agreement before it produces recurring revenue. Each of those steps changes the probability and timing of cash generation. A partnership announcement therefore belongs on a different level of evidence from repeat shipments to a paying customer.

The revenue base remains a mixture of non-recurring engineering work and products. POET reported $1.073 million of revenue in the first half of 2026, while its August 13 discussion described the transition from development toward commercial production. Engineering revenue is useful because customers are paying for work, but it does not automatically show the volume, margin or continuity of a product business. The product contribution and the repeat nature of orders matter as much as the aggregate growth rate. Source Source

There are also different products and generations within the opportunity. Optical engines for high-speed modules and external light sources do not necessarily qualify or ramp at the same time. A successful milestone on one product should not be generalized to the whole portfolio. The commercial question is which product has reached which customer, with what acceptance conditions and with what financial contribution. That keeps the analysis tied to evidence that can affect the next results rather than the size of the AI market in general.

03 The next milestones and what would count as a pass

The company’s August 13, 2026 results announcement maintained its expectation of an optical-engine production ramp in the second half of 2026. For that window to support the operating case, subsequent disclosures need to show the transition from units supplied for qualification toward accepted commercial shipments. A larger shipment count alone would be less persuasive if it consisted primarily of samples that do not produce meaningful revenue. Source

The precise wording matters. The CEO described the ramp as “remaining on schedule for the second half of 2026”, while the outlook paragraph spoke of beginning to ship “substantial numbers of production units for qualification in the remaining quarters of 2026” and said the company “will make additional announcements and updates in September, subject to the prevailing confidentiality agreements” and the risks in its cautionary note. The only POET report furnished to the SEC on Form 6-K in September was the September 4 conference announcement; no quantified shipment, qualification or order update had been furnished through October 5, 2026 (Merlintrader check of the EDGAR filing index). That does not mean progress is absent, but it means the September update the company referred to has not taken the form of a dated, quantified filing. Source EDGAR 6-K list

Two further company targets can be checked against the next results. The July 14 company FAQ said POET is targeting more than 30,000 optical-engine shipments across 2026, and that samples of the 1.6T 2×DR4 module developed with Lessengers were targeted for Q3 2026, a quarter that ended on September 30. Neither target had been confirmed as met in a company filing by October 5. The third-quarter report is the natural place for that evidence; the company has scheduled it for November 16, 2026 (release); last year the Q3 results were released on November 13. Source Source

The June 30, 2026 management discussion provides more specific product-development windows: light-source and 800G/1.6T transmitter prototypes in the fourth quarter of 2026, followed by production targets in the second quarter of 2027. It lists a module-development prototype target in the first quarter of 2027 and a production target in the third quarter of 2027. These are management milestones for particular development activities, not guaranteed customer order dates. They are a separate track from the ramp of existing products. Source

The closest fixed financial date is October 31, 2026, when a $1 million installment is due to Sanan under the purchase terms for the remaining interest in Super Photonics. That payment is small relative to June liquidity, but it is an actual contractual date. It has a different status from an operational target that depends on qualification or equipment commissioning. Source

POET’s September 4 announcement concerned an IFOC presentation on September 8 and an exhibition at CIOE on September 9–11, 2026. Those dates belong to the past event record, not the future catalyst calendar. Industry exposure can help generate commercial contacts, but a scheduled presentation does not show an order or completed qualification. The next meaningful operating update would need to describe progress beyond the existence of those events. Source

04 Lumilens: the order, the conditions and the customer incentive

The Lumilens agreement is the most important distinction between commercial potential and recognized business. POET’s August 13 release describes an initial $50 million purchase order for Optical Interposer-based engines and a broader relationship that could scale above $500 million over five years. The company’s July 14 FAQ explicitly ties revenue to module development, qualification and manufacturing expansion. The larger figure is therefore a possible cumulative outcome, not a completed sale or an unconditional revenue balance. Source Source

An initial purchase order is more substantial than a statement that two companies intend to cooperate. It identifies a commercial commitment within the relationship. Nevertheless, timing still depends on what must be delivered and accepted. The most useful follow-up would connect technical milestones with shipment schedules, recognized sales and payments. A trader should be able to see the progression without assuming that the entire initial order lands in a particular reporting year.

The company’s own schedule for this program is explicit: fulfilment of the purchase orders and the associated revenues “is subject to the successful development and ultimate qualification of the modules, as well as the successful scaling of manufacturing capability”, engineering samples are expected in late 2026, and the production ramp is aligned to hyperscaler customer deployments in 2027. The May 14 announcement specifies engines based on the Electrical-Optical Interposer (EOI), the platform at the center of the joint program with Lumilens, while the August 13 release refers to the same order as Optical Interposer-based engines; the company uses both descriptions. In Merlintrader’s reading, most of the $50 million initial order is therefore unlikely to be recognized as revenue in 2026 on the company’s own timetable; this is an inference, not a company statement. Source

Customer incentives also affect the economics. The May 14 announcement states that POET granted Lumilens a warrant for up to 22,921,408 common shares at $8.25, exercisable over nine years; the June financial statements record the same 22,921,408 warrants as granted to a customer in connection with a supply agreement for up to $500 million of products. Of these, 2,292,140 were vested and exercisable; the remaining 20,629,268 vest in tranches based on cumulative payments by Lumilens toward future purchase orders totaling up to $500 million. The balance sheet recorded $30.142 million of deferred customer consideration associated with the vested warrants, to be amortized as product revenue from the customer is recognized. The commercial relationship therefore includes an equity-based economic incentive alongside its purchasing potential. Source

These figures are neither revenue nor a cash payment made in the quarter. They describe a separate accounting and ownership consequence. Their significance is that the value of the customer relationship must be assessed after the incentive and eventual dilution, not solely from the headline order size. A good commercial outcome can justify an incentive; the incentive itself does not prove that the outcome has occurred.

05 Other orders and the breadth of commercial demand

POET disclosed on April 27, 2026 that all purchase orders received from Celestial AI had been cancelled, including the initial production orders announced in 2023. Marvell, which acquired Celestial AI, sent written notice on April 23. According to POET’s announcement, Marvell cited disclosures of order and shipping information that it considered contrary to confidentiality obligations. This is the stated reason in the release, not a judicial finding. Cancelled orders are not active backlog. POET Technologies press release: purchase order update.

A separate March 16, 2026 announcement describes joint development with LITEON Technology of optical modules using POET’s interposer platform. At that date, prototypes were expected in late 2026 and high-volume production in 2027. The collaboration was not disclosed as a quantified purchase order and is not part of the Lumilens order value. Those development targets remain different from completed deliveries or recognized revenue. POET exhibit 99.1, SEC filing.

The August 13, 2026 release disclosed a new $2.4 million purchase order from an existing customer after the June quarter ended. It also described an agreement with a Tier 1 laser company to develop an external light-source engine and an exclusive component arrangement intended to improve the output power of the Blazar hybrid laser. These are three different developments: an order, a development agreement and a supply arrangement. Adding them into a single revenue estimate would mix different levels of certainty. Source

The July 14 company FAQ also discussed an initial order exceeding $5 million for POET Infinity 800G engines, announced in October 2025 and targeted for shipment in the second half of 2026. That earlier order provides another commercial reference point for assessing the production ramp. The relevant next step is evidence of execution against the shipment target, with the resulting sales reported in the appropriate period. Source

At the June 26 annual meeting, the CEO said POET has more than ten active customer engagements that combined are expected to exceed $100 million in future annual revenue, including the Lumilens agreement, the 800G order and a significant NRE agreement for external light-source applications from a new customer. That is a management expectation, not backlog: no filing quantifies how much of the $100 million is under purchase order. Source

Commercial breadth reduces risk only when it becomes economically meaningful. Several development relationships can still depend on the same manufacturing process, limited engineering resources or industry spending cycle. They can also require different customer-specific adaptations, making a long list of engagements expensive to serve. Repeated orders and successful deliveries across customers would be stronger evidence of a scalable platform than the count of announced relationships.

The light-source work is strategically relevant because it extends the application of POET’s integration technology. It does not, however, make every announced collaboration a near-term sales catalyst. Blazar’s scaling objective was placed in 2028 in the June 30, 2026 update. That belongs to the longer product roadmap. The nearer-term picture depends on the products and orders expected to contribute before that stage. Source

06 Quarterly results: growth from a very small base

Revenue reached $569,925 in the quarter ended June 30, 2026, compared with $268,469 a year earlier and $503,389 in the March quarter. The company described this as its sixth consecutive quarter of sequential revenue growth. The direction is positive, but the absolute sales base remains small relative to both the resources committed and the market’s expectations for commercial expansion. Percentage growth is most useful when considered alongside the actual dollars. Source Source

The second quarter’s IFRS operating expenses totaled $20.760 million, including $6.993 million of research and development and $13.767 million of selling, general and administrative expenses. The resulting operating loss was $20.190 million. The net loss was lower, at $11.338 million, because items below the operating result included a $5.532 million warrant fair-value gain and $4.299 million of other income, including interest, partly offset by a $0.911 million unrealized foreign-exchange loss and $0.068 million of interest expense. Those contributions are economically different from a product business covering its costs. Source

The narrower net loss should therefore be interpreted carefully. Interest income reflects the benefit of a large funded balance sheet; the warrant valuation movement is non-cash and can reverse. Neither is evidence that optical products have reached operating break-even. Conversely, investment in staff and manufacturing before a ramp may depress operating results before its revenue benefits appear. The analysis needs both sides of that timing gap.

Financing also affected expenses. Financial advisory fees were $6.173 million in the June quarter and $9.425 million in the first half of 2026. Those costs help explain why a simple projection of the quarter’s expense level may be misleading. Raising the capital had a real cost, but these fees are tied to financing activity rather than to production, so they are not a reliable guide to the recurring quarterly cost base. Later results will provide a better view of the cost base after the financing activity. Source Source

Cash use also rose within the half. The company reported operating cash flow of ($12.2) million in the June quarter, against ($8.8) million in the March quarter and ($7.8) million a year earlier. Research and development ($5.8 million against $4.5 million) and stock-based compensation ($3.8 million against $3.5 million) rose from the March quarter, while wages and benefits, which included bonuses in the first quarter, were lower than in Q1 but well above a year earlier; headcount was put at about 115 people at the end of June, with plans announced at the annual meeting to add about 50 more within a few months. A higher run rate is consistent with the planned ramp, but it also means the half-year average understates the current pace of spending. Source Source Source

07 Cash, monthly burn and the limits of a historical runway

At June 30, 2026, POET held $432.532 million of cash and cash equivalents and $363.810 million of short-term investments. The calculated combined balance was $796.342 million. The short-term investments were guaranteed investment certificates at Canadian chartered banks, with maturities within a year. This is a substantial liquidity reserve, although it comprises two distinct balance-sheet categories. Source

Operations used $21.080 million in the six months ended June 30, 2026, and capital equipment purchases used a further $5.445 million. The calculated combined consumption was $26.525 million, or approximately $4.421 million per month. That measure uses operating cash flow plus equipment expenditure and excludes separate strategic investment and lending activity. It is a historical rate derived from the reported half-year, not management’s forecast for the next month. Source

Using the June quarter alone gives a different picture. Annualizing the reported ($12.2) million of second-quarter operating cash flow gives about $49 million a year of operating cash use, before any equipment. On top of that comes the approximately $50 million equipment plan for the second half of 2026 alone; equipment spending after December 2026 has not been disclosed (Merlintrader calculation, not company guidance). Even with both items, June liquidity of $796.3 million would cover several years at those rates, so the main question remains how productively the money is deployed. Source Source

Company communications also use different liquidity figures. The July 14 FAQ said POET held “$830M+ in cash and short-term investments” as of June 2026, while the June 30 balance sheet filed on August 13 shows $796.3 million. The $830 million figure matches the equity the CEO said had been raised over the preceding twelve months, not the filed quarter-end balance. The filed figure is the one used throughout this report. Source Source

Dividing June liquidity by that historical monthly rate gives approximately 180 months of mechanical coverage. The result illustrates the size of the cash reserve relative to the earlier business; it is unsuitable as a production-ramp runway forecast. The announced equipment plan alone called for approximately $50 million during the second half of 2026, far above equipment spending in the preceding half. Staffing, working capital, strategic transactions and customer timing can change consumption further. Source Source

The practical conclusion is that near-term survival financing is less central to the thesis than capital allocation and commercial execution. A large reserve allows management to build capacity and absorb delays. It also gives management more money to commit before demand is established. The next cash-flow statements should show how much of the reserve is funding productive capacity, how much is financing the operating deficit and whether customer collections are beginning to offset either requirement.

08 Manufacturing capacity: annual capability versus a monthly target

Sandeep Kumar’s appointment as Chief Operating Officer, reporting to the CEO, became effective May 11, 2026 and was announced May 12. The company described his prior responsibilities in manufacturing, supply chain, engineering and quality during more than 18 years at Silicon Labs. The appointment identifies operational leadership; it does not itself demonstrate improved yields or achievement of POET’s manufacturing targets. POET exhibit 99.1, SEC filing.

POET’s Malaysian manufacturing model involves Globetronics Manufacturing for optical-engine assembly and test and NationGate for light-source activities. The July 14, 2026 company explanation described annual capacity of approximately one million optical engines at the Globetronics facility. The June 30 update set a much larger objective of one million units per month by the end of 2027. These are different periods and different stages of expansion; the monthly figure is a target, not installed output. The company itself called the end-2027 goal a more than tenfold increase from current production capacity. Source Source

The June update also outlined approximately $50 million of initial equipment investment in the second half of 2026. The amount describes a spending plan, not a balance-sheet asset already commissioned or a guarantee that all planned capacity will be productive on schedule. Equipment must be delivered, installed and integrated into a process capable of meeting customer requirements. Yield and acceptance determine how much theoretical capacity becomes saleable output. Source

The August MD&A gives the physical starting point: an approximately 10,000-square-foot Globetronics clean room in Penang, where all wafer-level processing equipment is installed in a line with capacity for one million optical engines a year, and a cleanroom of comparable size at NationGate where light-source equipment was being installed. At the May 18 closing, the CEO described a roughly tenfold expansion of both wafer production and optical-engine assembly to support higher-volume manufacturing into 2027. Source Source

This creates a useful sequence for evaluating announcements. An equipment order demonstrates commitment; installation demonstrates physical progress; qualification demonstrates that the process or product meets specified requirements; customer acceptance and recurring deliveries demonstrate commercialization. Skipping directly from the first step to an assumption about mature revenue would understate the execution risk.

The August 13 management discussion described the transfer of Super Photonics equipment, the closure of its operations and the remaining formal wind-up work. That change supports the shift toward the Malaysian manufacturing setup. It does not mean POET has no remaining activity in China: the company also described operations in Shenzhen. Geographic concentration, the continuity of suppliers and coordination across facilities remain operational considerations even after one manufacturing arrangement is replaced. Source Source

09 Debt and strategic assets are separate from operating liquidity

The principal debt item was $5.8 million owed to Sanan at June 30, 2026, following the purchase of the remaining interest in Super Photonics. The remaining scheduled installments were $1 million on October 31, 2026, $1.3 million in October 2027, $1.6 million in October 2028 and $1.9 million in October 2029. The obligation is interest-free, but it is still debt and prevents the company from being accurately described as debt-free. Source

Sanan can convert unpaid consideration into POET shares using a market-linked price based on the greater of the preceding trading day’s closing price and the applicable thirty-day weighted average. The financial statements classify the obligation as current because of the conversion right. That presentation does not mean the entire cash schedule is due immediately, and the conversion mechanism does not show a fixed number of future shares. Source

On the asset side, POET had a $30.644 million loan receivable at June 30, 2026. The underlying advances totaled $30 million, earn interest at 6% and have contractual maturity or liquidity-event provisions. The agreement also provides for conversion into the borrower’s equity under specified conditions. This is money POET has advanced, rather than a borrowing by POET, and it is not part of cash available for equipment or payroll. The filings do not name the borrower; the three advances were made on January 7, January 21 and April 23, 2026, and the MD&A mentions professional fees for due diligence related to the loan. Source

The company also recorded a $2.955 million investment representing a 4.99% interest in Lessengers at June 30, 2026. That investment supports a strategic relationship but is different from a short-term bank investment. The distinction matters when assessing the financial cushion: bank liquidity, a strategic loan and a private-company equity stake have different availability and risks. Combining all financial assets into one cash number would overstate immediate spending flexibility. Source

10 The financing that changed the shareholder denominator

POET’s common shares increased from 132,021,526 at December 31, 2025 to 173,035,169 at June 30, 2026. The August 13 management discussion then reported 173,058,088 shares outstanding. These are dated actual counts, rather than the weighted-average share count used in calculating earnings per share. The increase gave the company capital while reducing each pre-existing share’s percentage interest in the business. Source Source

The May 18, 2026 financing issued 19,047,620 common shares with warrants for the same number of additional shares, raising $400.000 million gross at $21 per package. The accompanying warrants have a $26.25 exercise price and expire on May 18, 2029. The original subscription price paid for a package of a share and a warrant, so it is not a simple valuation certificate for an unaccompanied common share. Source Source

The May 18 release did not name the buyer. Before the offering, MMCAP International Inc. SPC and MM Asset Management Inc. reported in a Schedule 13G/A filed May 15, 2026 beneficial ownership of 14,516,820 shares as of March 31, 2026 (9.99%), made up of 1,494,038 common shares and 13,022,782 shares underlying warrants. A further 13G/A filed on May 20, 2026 reported beneficial ownership of exactly 19,047,620 shares as of May 18, about 11.0% of the class; in Merlintrader’s reading the identical number points to MMCAP as the single investor, although the filing itself does not say so and MMCAP already held warrant-based exposure before May. A further amendment filed on August 14 reported 19,155,361 shares as of June 30, “which consists entirely of Common Shares underlying warrants”, equal to 9.99%. The filings do not explain the change; they indicate that at June 30 the reported position no longer included common shares, only warrants. Schedule 13G/A, May 15 Schedule 13G/A, May 20 Schedule 13G/A, Aug 14 Source

The company had also issued 20,689,656 common shares at $7.25 in January 2026 to institutional investors through a placement agent, raising approximately $150 million gross. Together, the financings explain much of the transformation in the balance sheet and ownership denominator. Their benefit is the cash available for execution. Their cost includes issuance expenses, additional shares and, for the May package, the possibility of later warrant dilution. Source Source

The May offering used an automatic shelf registration that became effective on January 22, 2026. A registration provides a mechanism for issuing securities; it is not another funded asset and does not by itself prove that more shares have been sold. The company’s enlarged liquidity reserve reduces the immediate need to rely on further issuance, but it does not remove management’s ability or potential incentive to raise capital for future expansion. Source

At the June 26 annual meeting the CEO said POET had raised $830 million in equity over the preceding twelve months, with the potential to raise up to a further $661 million if outstanding warrants are exercised. The stated use of the May proceeds included manufacturing expansion, corporate development “including targeted acquisitions”, R&D, the light-source business and working capital. Acquisitions paid in shares would be another possible source of dilution. Source Source

11 Warrants, employee awards and the authorized share structure

POET reported 78,734,968 warrants outstanding at June 30 and August 13, 2026. The total includes financing warrants and customer warrants with different exercise prices, vesting conditions and maturities. It therefore describes potential dilution across several instruments, rather than a block that must all become common shares immediately. Any estimate of proceeds also needs to respect which awards can be exercised and on what terms. Source Source

The 22,921,408 Lumilens warrants form part of that total, so adding them again would double-count. At June 30, 2026, only 2,292,140 of those customer warrants were vested and exercisable; additional vesting depended on payment milestones. Likewise, the 19,047,620 warrants attached to the May financing are already included in the overall balance. Double-counting these subcategories would materially overstate dilution. Source

The exercise prices matter more than the headline. Using the June 30 warrant table, warrants with exercise prices at or below the October 2, 2026 Nasdaq close of $7.79 total 36,765,940 shares (series priced from $1.09 to $7.12, expiring between January 2029 and October 2030), which would bring in about $211.7 million if all were exercised for cash (Merlintrader calculation). The 19,047,620 May warrants at $26.25 and the 22,921,408 Lumilens warrants at $8.25, of which only 2,292,140 are vested, were above that price. The Lumilens warrant also has a cashless-exercise feature, so its share count on exercise can vary. Source Source

The company also had 5,369,393 options and 3,885,953 restricted share units outstanding at June 30, 2026. The August 13 results release separately disclosed an August 11 grant of 2,453,271 restricted share units to officers, with annual vesting over three years. These are compensation awards, not evidence that executives purchased common shares with their own cash. Award vesting and settlement also have a different timing from the grant announcement. Source Source

Authorized common shares are unlimited. The omnibus compensation plan approved in June 2026 was a fixed plan permitting 34,592,565 shares, with an increase requiring shareholder approval and subject to the stated percentage limit. Unlimited authorized common stock and a fixed compensation-plan reserve are different concepts. The plan reserve does not increase automatically each year, while unlimited authorized stock means the capital structure does not have a simple fixed authorized-share ceiling that protects existing holders from future issuance. Source Source

12 Market positioning, ownership and insider signals

The reference Nasdaq closing price is $7.79 on October 2, 2026, the last session before this update. At that price the 173,058,088 shares reported on August 13 have a market value of about $1.35 billion, of which the June 30 liquidity of $796.3 million represents about 59% (Merlintrader calculation combining figures of different dates; it is context, not a valuation). Source Source

Nasdaq reported short interest of 22,826,238 shares at the September 15, 2026 settlement date, about 13.2% of the 173,058,088 shares outstanding on August 13 (Merlintrader calculation) and 2.67 days to cover on Nasdaq’s average-volume figures. The position was 22,239,486 shares at August 31 and 27,273,807 at August 14, so it fell by about 16% over the month. Short interest is published twice a month with a lag, so each figure describes the position on its settlement date. Source

The short positioning can amplify reactions to qualification news, unexpected orders or disappointing execution. It does not create a guaranteed squeeze or establish that holders must cover within the reported days-to-cover figure. Days to cover relates short positions to average daily volume. Liquidity, borrow conditions, new issuance and the willingness of counterparties to trade determine the actual market response.

The March 20, 2026 ownership table in the annual report named MM Asset Management/MMCAP with 1,526,205 shares, based on an earlier disclosure. Section 10 sets out MMCAP’s later Schedule 13G/A filings, from 14,516,820 shares at March 31 (mostly warrant shares) to the positions reported around the May financing. Other 5% filings since May come mainly from trading and market-making firms whose reported positions include options: Marex reported 9,150,000 shares (6.0%) as of May 14; Jane Street 9,514,777 (5.5%) and Citadel Securities entities 10,085,671 (5.8%) as of June 30; Susquehanna entities 9,808,403 (5.7%) as of June 30, including options to buy 9,122,200 shares; and Group One Trading went from 9,445,376 (5.5%) at June 30 to 1,255,050 (0.7%) at August 31. These positions can change quickly and are not long-term strategic stakes. Source 13G Marex 13G/A Jane Street 13G Citadel 13G Susquehanna 13G/A Group One

For insider interpretation, the August 3 announcement awarded 21,460 restricted share units each to the two newly appointed directors, Dr. Bardia Pezeshki and Jean F. Rankin, with vesting scheduled for June 26, 2027; on August 11 the board granted 2,453,271 RSUs to officers, sized at the $8.56 Nasdaq close of August 10 and vesting over three years. These are compensation and future ownership exposure, not open-market purchase signals. As a foreign private issuer, POET’s insiders do not file U.S. Forms 4; their trades are reported in Canada on SEDI, outside the scope of this analysis. Source Source

Two governance points are open. On May 15 the company said CFO Thomas Mika intends to retire “sometime this year” and that the board was searching for a successor; no successor had been announced in a filing by October 5, 2026. Separately, in April the company said it expected to be treated as a passive foreign investment company (PFIC) for 2025 and that the board had approved a redomicile to the United States to remove that risk for future years; on August 13 the board decided that redomiciling is “not in the best interests of the Company” at present. The company has said it believes it will not be a PFIC for 2026, but that depends on its income and assets for the year. U.S. holders face tax consequences if the PFIC classification applies; this is general information, not tax advice. Source Source Source

13 Red flags, the next operating test and the overall assessment

The first red flag is an expanding gap between announced commercial potential and recognized sales. The initial Lumilens order and the later customer order establish concrete opportunities, but development and qualification determine the timing of their economic contribution. If production targets move repeatedly while spending rises, the cash reserve would be financing a longer and less certain path to scale. A larger market opportunity would not repair that execution gap by itself.

A second concern is capital committed ahead of evidence. The equipment program, strategic loan and private investment can all support a broader platform. They also reduce the portion of financial resources held in immediately available forms and increase the return that the business must eventually earn. The next financial statement should make it possible to distinguish cash used for the operating deficit from money deployed into additional capacity or strategic assets.

Dilution is the third issue. Financing has substantially improved staying power, while common shares, warrants and compensation awards have expanded the claims on future results. A successful company outcome and a successful per-share outcome are related but not identical. The value created by the funded expansion needs to grow faster than the ownership denominator and the economic incentives attached to commercial agreements.

A fourth, smaller item is legal. The June-quarter financial statements say the company “was threatened with and named as defendants to a pending legal action”, that it does not expect a material effect and that it is assessing its response; the MD&A adds that professional fees rose partly because of the defense of a claim. The filings do not identify the claimant, the court or the amount, so the matter cannot be assessed independently. Source Source

The most informative next update would join four elements: which products passed customer milestones, what was shipped and accepted, how much revenue and cash followed, and what equipment and operating spending were required. A revenue increase without that financial context would leave an incomplete picture. A more expensive quarter could still represent progress if it delivers productive assets and qualified repeat demand, but the evidence needs to connect those costs to commercial results.

POET’s case rests on a funded transition from development to production. The June 30 balance sheet gives management substantial room to execute; the modest reported revenue base shows how much of the commercial story still lies ahead. The decisive issue is whether product qualification, manufacturing scale and customer payments begin to reinforce one another. Until that sequence becomes visible, large orders, a large cash balance and strong industry demand should each be assessed for what they demonstrate, without treating any one of them as proof of the whole outcome.